Toxicity and response to high-dose ifosfamide+mesna as salvage therapy for advanced breast cancer

G. G. Steger, C. Dittrich, O. Schlappack, R. Mader, C. Herold, W. P. Brade, A. Keller, K. Moser

Research output: Contribution to journalArticle

Abstract

Twenty-six cycles of high-dose ifosfamide+mesna (HD-IFO+M) were applied to seven female patients with advanced breast cancer refractory to prior treatment, using three different durations of continuous infusion (4, 24, and 48 h) every 3 weeks. To evaluate the most tolerable time schedule, the duration of the infusions was changed periodically in each patient. Toxicity was low in general, but continuous infusion of HD-IFO+M over 24 h appeared to be the best tolerated. On partial response lasting 27 weeks was achieved and four patients achieved stable disease lasting from 9 to 12 weeks.

Original languageEnglish (US)
Pages (from-to)602-604
Number of pages3
JournalJournal of Cancer Research and Clinical Oncology
Volume114
Issue number6
DOIs
StatePublished - Dec 1 1988

Keywords

  • Breast cancer
  • Ifosfamide+mesna
  • Salvage therapy
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Toxicity and response to high-dose ifosfamide+mesna as salvage therapy for advanced breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Steger, G. G., Dittrich, C., Schlappack, O., Mader, R., Herold, C., Brade, W. P., Keller, A., & Moser, K. (1988). Toxicity and response to high-dose ifosfamide+mesna as salvage therapy for advanced breast cancer. Journal of Cancer Research and Clinical Oncology, 114(6), 602-604. https://doi.org/10.1007/BF00398184